MAZE — Maze Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$26.28
-$0.25 (-0.94%)
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on NASDAQ. It is led by Jason V. Coloma M.B.A., M.P.H., Ph.D., based in 171 Oyster Point Blvd, South San Francisco, CA, United States, 94080, with about 125 employees. Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Latest reported MAZE revenue for 2025-06-30 was $0. Net income was -$66.5M. MAZE currently screens at market cap $525.3M.
Use this MAZE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MAZE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MAZE SEC filings page. Lician reads the product cache first so this HTML stays unique to Maze Therapeutics, Inc. Common Stock even when a live quote feed is slow.
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Key Statistics
Market Cap
$525.32M
Volume
97,602
Previous Close
$30.42
Day Range
$29.33 – $30.40
EPS
-$0.66
Revenue
$0.00
Net Income
-$96.55M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
125
MAZE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2025 | FY2025 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $2.50M | $165.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$96.55M | -$66.47M | -$32.79M | $81.81M | $106.56M |
| EPS (Diluted) | -$0.66 | -$0.77 | -$1.15 | -$10.25 | $3.22 |
Total Assets
$422.06M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$316.77M
Operating Cash Flow
-$84.21M
Free Cash Flow
$0.00
Maze Therapeutics, Inc. Common Stock Company Information
- CEO & Director
- Jason V. Coloma M.B.A., M.P.H., Ph.D.
- Headquarters
- 171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
- Website
- www.mazetx.com
- Phone
- 650 850 5070
- IPO / Founded
- 2025-01-31
- Sector
- Healthcare
- Industry
- Biotechnology